Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with Lucentis in patients with neovascular age-related macular degeneration

Detalles Bibliográficos
Autores principales: Shah, Chirag, Sonkusare, Kishore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229946/
https://www.ncbi.nlm.nih.gov/pubmed/36872752
http://dx.doi.org/10.4103/IJO.IJO_2609_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229946/
https://www.ncbi.nlm.nih.gov/pubmed/36872752
http://dx.doi.org/10.4103/IJO.IJO_2609_22

Ejemplares similares